ADVISORY, March 29, 2017 (GLOBE NEWSWIRE) --
What:
Xenetic Biosciences, Inc. (Nasdaq:XBIO), a clinical-stage biopharmaceutical company focused on the discovery, research
and development of next-generation biologic drugs and novel orphan oncology therapeutics, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, M Scott Maguire, Chief Executive Officer will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Thursday, March 30, 2017 – 9:15 a.m. to 9:30 a.m. ET
Xenetic Biosciences Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475
jenene@jenenethomascommunications.com
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please
visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your
choice.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, research and
development of next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug development
platforms include PolyXen™, which enables next generation biologic drugs by improving their half-life and other
pharmacological properties. Xenetic's lead investigational product candidates include oncology therapeutic XBIO-101 (sodium
cridanimod) for the treatment of progesterone resistant endometrial cancer (EC), and a polysialylated form of erythropoietin for
the treatment of anemia in pre-dialysis patients with chronic kidney disease.
Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare)
to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration
relies on Xenetic's PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of
improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is a significant stockholder
of the Company, having invested $10 million in the Company during 2014. The agreement is an exclusive research, development
and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary
technology in combination with Shire's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the
agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100
million plus royalties on sales.
Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology
therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, Facebook and Google+.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public
company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and
execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than
85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed
companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.
-NDAQA-
